Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jun;71(6):1181–1187. doi: 10.1038/bjc.1995.230

Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.

S M Castellino 1, H S Friedman 1, G B Elion 1, E T Ong 1, S L Marcelli 1, R Page 1, D D Bigner 1, M W Dewhirst 1
PMCID: PMC2033851  PMID: 7779708

Abstract

Flunarizine, a diphenylpiperazine calcium channel blocker, is known to increase tumor blood flow. It also interferes with calmodulin function, repair of DNA damage and drug resistance associated with P-glycoprotein. Flunarizine was tested for its ability to modulate either cyclophosphamide- or melphalan-induced growth delay for a drug-resistant rhabdomyosarcoma xenograft (TE-671 MR) and the drug-sensitive parent line (TE-671), in which P-glycoprotein is not involved in the mechanism of drug resistance. Tumour blood flow was increased by 30% after a flunarizine dose of 4 mg kg-1, but no modification in growth delay was induced by melphalan (12 mg kg-1). In contrast, a 60 mg kg-1 dose of flunarizine had no effect on tumour blood flow, but the same dose created significant enhancement in melphalan-induced tumour regrowth delay in both tumour lines. The dose-modifying factor for flunarizine as an adjuvant to melphalan was approximately 2 for both tumour lines. Although blood flow measurements were not performed with the combination of flunarizine and melphalan, the results from flunarizine alone suggested that augmentation of melphalan cytotoxicity is not mediated by changes in blood flow. In contrast, flunarizine did not affect drug sensitivity to cyclophosphamide in groups of animals bearing the drug-sensitive parent tumour line. These results suggest that the mechanism of drug sensitivity modification by flunarizine is not related to modification of tumour blood flow, but may be mediated by modification of transport mechanisms that are differentially responsible for cellular uptake and retention of melphalan as compared with cyclophosphamide.

Full text

PDF
1181

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acker J. C., Dewhirst M. W., Honoré G. M., Samulski T. V., Tucker J. A., Oleson J. R. Blood perfusion measurements in human tumours: evaluation of laser Doppler methods. Int J Hyperthermia. 1990 Mar-Apr;6(2):287–304. doi: 10.3109/02656739009141139. [DOI] [PubMed] [Google Scholar]
  2. Adams G. E., Stratford I. J., Godden J., Howells N. Enhancement of the anti-tumor effect of melphalan in experimental mice by some vaso-active agents. Int J Radiat Oncol Biol Phys. 1989 May;16(5):1137–1139. doi: 10.1016/0360-3016(89)90268-x. [DOI] [PubMed] [Google Scholar]
  3. Bullard D. E., Schold S. C., Jr, Bigner S. H., Bigner D. D. Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol. 1981 Jul;40(4):410–427. doi: 10.1097/00005072-198107000-00005. [DOI] [PubMed] [Google Scholar]
  4. Chafouleas J. G., Bolton W. E., Means A. R. Potentiation of bleomycin lethality by anticalmodulin drugs: a role for calmodulin in DNA repair. Science. 1984 Jun 22;224(4655):1346–1348. doi: 10.1126/science.6203171. [DOI] [PubMed] [Google Scholar]
  5. Dewhirst M. W., Ong E. T., Klitzman B., Secomb T. W., Vinuya R. Z., Dodge R., Brizel D., Gross J. F. Perivascular oxygen tensions in a transplantable mammary tumor growing in a dorsal flap window chamber. Radiat Res. 1992 May;130(2):171–182. [PubMed] [Google Scholar]
  6. Dewhirst M. W., Ong E. T., Madwed D., Klitzman B., Secomb T., Brizel D., Bonaventura J., Rosner G., Kavanagh B., Edwards J. Effects of the calcium channel blocker flunarizine on the hemodynamics and oxygenation of tumor microvasculature. Radiat Res. 1992 Oct;132(1):61–68. [PubMed] [Google Scholar]
  7. Fenton B. M., Sutherland R. M. Effect of flunarizine on micro-regional distributions of intravascular HbO2 saturations in RIF-1 and KHT sarcomas. Int J Radiat Oncol Biol Phys. 1992;22(3):447–450. doi: 10.1016/0360-3016(92)90850-h. [DOI] [PubMed] [Google Scholar]
  8. Friedman H. S., Schold S. C., Jr, Bigner D. D. Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice. Cancer Res. 1986 Jan;46(1):224–228. [PubMed] [Google Scholar]
  9. Friedman H. S., Schold S. C., Jr, Mahaley M. S., Jr, Colvin O. M., Oakes W. J., Vick N. A., Burger P. C., Bigner S. H., Borowitz M., Halperin E. C. Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma. J Clin Oncol. 1989 Jul;7(7):904–911. doi: 10.1200/JCO.1989.7.7.904. [DOI] [PubMed] [Google Scholar]
  10. Friedman H. S., Skapek S. X., Colvin O. M., Elion G. B., Blum M. R., Savina P. M., Hilton J., Schold S. C., Jr, Kurtzberg J., Bigner D. D. Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. Cancer Res. 1988 Oct 1;48(19):5397–5402. [PubMed] [Google Scholar]
  11. Godfraind T., Miller R., Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev. 1986 Dec;38(4):321–416. [PubMed] [Google Scholar]
  12. Gupta V., Singh S. V., Ahmad H., Medh R. D., Awasthi Y. C. Glutathione and glutathione S-transferases in a human plasma cell line resistant to melphalan. Biochem Pharmacol. 1989 Jun 15;38(12):1993–2000. doi: 10.1016/0006-2952(89)90499-1. [DOI] [PubMed] [Google Scholar]
  13. Hait W. N., Morris S., Lazo J. S., Figlin R. J., Durivage H. J., White K., Schwartz P. E. Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine. Cancer Chemother Pharmacol. 1989;23(6):358–362. doi: 10.1007/BF00435836. [DOI] [PubMed] [Google Scholar]
  14. Horowitz M. E., Etcubanas E., Christensen M. L., Houghton J. A., George S. L., Green A. A., Houghton P. J. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol. 1988 Feb;6(2):308–314. doi: 10.1200/JCO.1988.6.2.308. [DOI] [PubMed] [Google Scholar]
  15. Kaelin W. G., Jr, Shrivastav S., Jirtle R. L. Blood flow to primary tumors and lymph node metastases in SMT-2A tumor-bearing rats following intravenous flunarizine. Cancer Res. 1984 Mar;44(3):896–899. [PubMed] [Google Scholar]
  16. Kavanagh B. D., Coffey B. E., Needham D., Hochmuth R. M., Dewhirst M. W. The effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment. Br J Cancer. 1993 Apr;67(4):734–741. doi: 10.1038/bjc.1993.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kikuchi Y., Miyauchi M., Kizawa I., Oomori K., Kato K. Establishment of a cisplatin-resistant human ovarian cancer cell line. J Natl Cancer Inst. 1986 Dec;77(6):1181–1185. [PubMed] [Google Scholar]
  18. Lazo J. S., Chen D. L., Gallicchio V. S., Hait W. N. Increased lethality of calmodulin antagonists and bleomycin to human bone marrow and bleomycin-resistant malignant cells. Cancer Res. 1986 May;46(5):2236–2240. [PubMed] [Google Scholar]
  19. Lee F. Y., Workman P. Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards. Cancer Chemother Pharmacol. 1986;17(1):30–37. doi: 10.1007/BF00299862. [DOI] [PubMed] [Google Scholar]
  20. Lilley E. R., Elion G. B., Dewhirst M. W., Schold S. C., Jr, Blum M. R., Savina P. M., Laskowitz D. T., Bigner D. D., Friedman H. S. Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR. Cancer Res. 1991 Aug 1;51(15):3906–3909. [PubMed] [Google Scholar]
  21. Lugnier C., Follenius A., Gerard D., Stoclet J. C. Bepridil and flunarizine as calmodulin inhibitors. Eur J Pharmacol. 1984 Feb 10;98(1):157–158. doi: 10.1016/0014-2999(84)90128-6. [DOI] [PubMed] [Google Scholar]
  22. McAllister R. M., Isaacs H., Rongey R., Peer M., Au W., Soukup S. W., Gardner M. B. Establishment of a human medulloblastoma cell line. Int J Cancer. 1977 Aug 15;20(2):206–212. doi: 10.1002/ijc.2910200207. [DOI] [PubMed] [Google Scholar]
  23. Miller L., Deffie A. M., Bose R., Goldenberg G. J. Modulation of melphalan uptake in murine L5178Y lymphoblasts in vitro by changes in ionic environment. Biochem Pharmacol. 1992 Mar 3;43(5):1154–1158. doi: 10.1016/0006-2952(92)90627-u. [DOI] [PubMed] [Google Scholar]
  24. Parsons P. G., Carter F. B., Morrison L., Regius Mary Sister Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res. 1981 Apr;41(4):1525–1534. [PubMed] [Google Scholar]
  25. Redwood W. R., Colvin M. Transport of melphalan by sensitive and resistant L1210 cells. Cancer Res. 1980 Apr;40(4):1144–1149. [PubMed] [Google Scholar]
  26. Robinson B. A., Clutterbuck R. D., Millar J. L., McElwain T. J. Effects of verapamil and alcohol on blood flow, melphalan uptake and cytotoxicity, in murine fibrosarcomas and human melanoma xenografts. Br J Cancer. 1986 May;53(5):607–614. doi: 10.1038/bjc.1986.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Rose W. C., Trader M. W., Dykes D. J., Laster W. R., Jr, Schabel F. M., Jr Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors. Cancer Treat Rep. 1978 Dec;62(12):2085–2093. [PubMed] [Google Scholar]
  28. Rosenberg M. C., Colvin O. M., Griffith O. W., Bigner S. H., Elion G. B., Horton J. K., Lilley E., Bigner D. D., Friedman H. S. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. Cancer Res. 1989 Dec 15;49(24 Pt 1):6917–6922. [PubMed] [Google Scholar]
  29. Sezzi M. L., Zupi G., De Luca G., Materazzi M., Bellelli L. Effects of a calcium-antagonist (flunarizine) on the in vitro growth of B16 mouse melanoma cells. Anticancer Res. 1984 Jul-Oct;4(4-5):229–234. [PubMed] [Google Scholar]
  30. Shenoy M. A., Biaglow J. E., Varnes M. E., Hetzel F. W. Inhibition of cultured human tumor cell oxygen utilization by chlorpromazine. Adv Exp Med Biol. 1983;159:359–368. doi: 10.1007/978-1-4684-7790-0_31. [DOI] [PubMed] [Google Scholar]
  31. Somfai-Relle S., Suzukake K., Vistica B. P., Vistica D. T. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem Pharmacol. 1984 Feb 1;33(3):485–490. doi: 10.1016/0006-2952(84)90245-4. [DOI] [PubMed] [Google Scholar]
  32. Stewart D. J., Evans W. K. Non-chemotherapeutic agents that potentiate chemotherapy efficacy. Cancer Treat Rev. 1989 Mar;16(1):1–40. doi: 10.1016/0305-7372(89)90002-9. [DOI] [PubMed] [Google Scholar]
  33. Stratton M. R., Darling J., Pilkington G. J., Lantos P. L., Reeves B. R., Cooper C. S. Characterization of the human cell line TE671. Carcinogenesis. 1989 May;10(5):899–905. doi: 10.1093/carcin/10.5.899. [DOI] [PubMed] [Google Scholar]
  34. Wood P. J., Hirst D. G. Calcium antagonists as radiation modifiers: site specificity in relation to tumor response. Int J Radiat Oncol Biol Phys. 1989 May;16(5):1141–1144. doi: 10.1016/0360-3016(89)90269-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES